原发性免疫缺陷病患者头颈癌发病率与结局分析
本研究基于TriNetX数据库和SEER 2017-2021数据,回顾性比较原发性免疫缺陷病(PID)患者与一般人群的头颈癌(HNC)发病率,并对HNC伴或不伴PID患者进行1:1倾向匹配分析结局。结果显示PID患者HNC风险显著增高(口腔和咽部癌SIR 6.55,95%CI 5.13-8.13),且HNC伴PID患者死亡风险(HR 1.39,95%CI 1.17-1.66)和营养不良风险(OR 1.34,95%CI 1.21-1.49)显著增加。
要点
- PID患者口腔和咽部癌风险显著高于一般人群(SIR 6.55)。
- HNC伴PID患者死亡风险增加39%(HR 1.39)。
- HNC伴PID患者营养不良风险增加34%(OR 1.34)。
核心结论
- PID患者头颈癌发病率显著高于一般人群。
- HNC伴PID患者术后并发症和死亡风险增加。
研究设计与样本
- 回顾性队列研究,使用TriNetX数据库和SEER 2017至2021数据。
- 比较PID患者与一般人群的HNC发病率。
- 对HNC伴与不伴PID患者进行1:1倾向匹配分析结局。
主要发现
- PID患者口腔和咽部癌总体SIR为6.55(95%CI 5.13-8.13)。
- HNC伴PID患者死亡风险HR为1.39(95%CI 1.17-1.66)。
- HNC伴PID患者营养不良风险OR为1.34(95%CI 1.21-1.49)。
临床怎么用
- 对PID患者应加强头颈癌筛查和监测。
- HNC伴PID患者需关注营养不良和死亡风险,优化围手术期管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Patients with primary immunodeficiency disorders (PID) have increased hematological cancer risk but the risk of head and neck cancer (HNC) is not well-established. Here, we sought to compare the risk of HNC among patients with PID to that of the general population. Furthermore, we report overall outcomes among HNC patients with and without PID. STUDY DESIGN: Retrospective cohort study. SETTING: TriNetX, a database containing millions of deidentified health records, and Surveillance, Epidemiology, and End Results (SEER) 2017 to 2021. METHODS: A comparative analysis of HNC incidence among patients with PID versus the general population. Outcomes analyses were conducted on 1:1 propensity matched cohorts of patients with HNC with and without PID. RESULTS: Patients with PID had a significantly increased risk of HNC compared to the general population with an overall SIR (95% CI) of 6.55 (5.13-8.13) for oral cavity and pharynx cancer. Among patients with HNC, those with PID had a significantly increased risk of mortality (HR 1.39, 95% CI 1.17-1.66) and malnutrition (OR 1.34, 95% CI 1.21-1.49). CONCLUSION: Patients with PID have significantly increased incidence of HNC compared to the general population. Moreover, HNC patients with PID face an increased risk of post-operative complications and mortality.
引用
- Wenger TA, Collet C, West J, et al. Rates and Outcomes of Head and Neck Cancer Among Patients With Primary Immunodeficiency Disorders. Otolaryngol Head Neck Surg. 2026. PMID: 42171009. doi:10.1002/ohn.70301
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。